Combretastatins: in vitro structure-activity relationship,mode of action and current clinical status

For the first time combretastatins were isolated from african willow tree combretum caffrum. subsequent studies have shown the impact of combretastatin a4 phosphate,a water-soluble prodrug,on endothelial cells in tumor vascular system. the same effect was not observed in the vascular system. this selectivity is associated with combretastatins mechanism of action: binding to colchicine domain of microtubules,which affects the cytoskeleton functionality of immature endothelial cells. at the same time,combretastatins directly induce cell death via apoptosis and/or mitotic catastrophe pathways. the combination of both elements makes combretastatin an anticancer compound of high efficiency. the cis-configuration is crucial for its biological activity. to date,many derivatives were synthesized. the attempts to resolve spontaneous isomerization to less active trans-stilbene derivative are still in progress. this issue seems to be overcome by incorporation of the ethene bridge with heterocyclic moiety in combretastatins structure. this modification retains the cis-configuration and prevents isomerization. nevertheless,combretastatin a4 phosphate disodium is still the most potent compound of this group. the combination therapy,which is the most effective treatment,includes combretastatin a4 phosphate (ca4p) and conventional chemotherapeutics and/or radiotherapy. ca4p is relatively well tolerated giving adverse events of moderate severity,which includes: nausea,vomiting,headache,and tumor pain. the aforementioned effects subside on the day of drug administration or on the following day. © 2016 institute of pharmacology,polish academy of sciences